Country/Region：France
Year of Investment：2015
Industry：Healthcare
Company Website：
Company Profile：
EYE TECH CARE was founded in 2008 in Lyon, France and a medical device company committed to the innovative use of therapeutic ultrasound technology to revolute glaucoma treatment.
EYE TECH CARE（ETC）innovatively applies high-intensity focused ultrasound technology to ophthalmology, exclusively researching, industrializing and manufacturing miniaturized probe transducers for ophthalmology. The device can accurately focus into the eye ciliary body and treat the glaucoma through thermal effects, namely the transformational glaucoma therapy- UCP ultrasound ciliary body angioplasty.
UCP ultrasound ciliary body angioplasty and related products have been extensively clinically proven and successfully treated more than 7,000 patients from all over the world, with sound therapeutic effect, convenient treatment, safe and no series side effects. The technology and products have been certified by European CE Mark, CFDA, etc., and have been actively promoted in Europe, China, the Middle East, India, South America and Africa.
Everpine Capital Added Value：
Everpine Capital effectively assembled experienced domestic operation and management team for ETC by the operation model “Overseas Technology + China Market”, which enable ETC technology and products to conduct clinical trials in many hospitals in China. In November, 2017, ETC obtained the CFDA the third category treatment product certification and registered Chinese trademark “Jing Que”.
With its extensive resource network in the medical field, Everpine Capital has established a wide range of strategic partners for ETC, including listed companies and groups on medical device sales channels, top ophthalmology department in the industry's top general hospitals and eye specialty hospitals , and connected to the most authoritative experts in the medical industry as advisers and consultants for the project in the Chinese market.
Under the deep participation and support of Everpine Capital, the company has operated nearly 1000 successful surgeries by EyeOP1 product and technology more than 100 ophthalmology department of general hospitals or ophthalmology hospitals in Beijing, Shanghai, Qingdao, Henan, Shanxi, Shaanxi, Gansu, Chongqing and Chengdu (including Ophthalmic Center of Sun Yat-sen University, Shanghai Ruijin Hospital, Tianjin Hospital, Beijing Tongren Hospital, Fudan University Eye and Otolaryngology Hospital, Aier Eye Hospital, etc.)With remarkable surgery effect and sound follow up result, EyeOP1 product and technology were unanimously recognized and recommended by ophthalmologists at home and abroad. Domestic hospitals and distributors responded positively, and the products have gradually participated in the procurement bidding process.
